Abstract: A method for producing a polysaccharide includes extracting from broccoli with hot water to obtain an extract, purifying the extract by a chromatography column, and hydrolyzing the purified extract with oxalic acid. The chromatography column can be a DEAE cellulose chromatography column. The polysaccharide produced can have innate immune stimulating activity.

Abstract: A substance having innate immune stimulating activity is a polysaccharide, which contains 25 to 50 parts by mole of galacturonic acid, 15 to 50 parts by mole of galactose, 0 to 7 parts by mole of glucose, 0 to 30 parts by mole of arabinose, 0 to 6 parts by mole of xylose, and 3 to 15 parts by mole of rhamnose as constituent sugars. The polysaccharide has a polygalacturonic acid chain having ?-1,4-linked galacturonic acid as a main chain. An innate immune stimulant can include the polysaccharide as an active component, which can be included in a food or drink.

Abstract: A substance having innate immune stimulating activity is a polysaccharide, which contains 25 to 50 parts by mole of galacturonic acid, 15 to 50 parts by mole of galactose, 0 to 7 parts by mole of glucose, 0 to 30 parts by mole of arabinose, 0 to 6 parts by mole of xylose, and 3 to 15 parts by mole of rhamnose as constituent sugars. The polysaccharide has a polygalacturonic acid chain having ?-1,4-linked galacturonic acid as a main chain. An innate immune stimulant can include the polysaccharide as an active component, which can be included in a food or drink.

Abstract: Lactic acid bacteria having high natural immunity activation ability and infection preventative/therapeutic containing said lactic acid bacteria or elements derived from said lactic acid bacteria, and a food/beverage containing these are provided. Lactic acid bacteria belonging to the genus Lactobacillus that are accession number NITE BP-02005 of the NITE NPMD, lactic acid bacteria having natural immunity activation ability that are these lactic acid bacteria or naturally or artificially mutated lactic acid bacteria thereof, lactic acid bacteria having a base sequence of the 16S rDNA region shown by SEQ ID NO: 1, a natural immunity-activating agent having as an active ingredient these lactic acid bacteria, dead cells of these lactic acid bacteria, or a treatment product of these lactic acid bacteria, an infection preventative/therapeutic containing as an active ingredient a peptide glycan of these lactic acid bacteria, and a food/beverage containing these are disclosed.

Abstract: Lactic acid bacteria having high natural immunity activation ability and infection preventative/therapeutic containing said lactic acid bacteria or elements derived from said lactic acid bacteria, and a food/beverage containing these are provided. Lactic acid bacteria belonging to the genus Lactobacillus that are accession number NITE BP-02005 of the NITE NPMD, lactic acid bacteria having natural immunity activation ability that are these lactic acid bacteria or naturally or artificially mutated lactic acid bacteria thereof, lactic acid bacteria having a base sequence of the 16S rDNA region shown by SEQ ID NO: 1, a natural immunity-activating agent having as an active ingredient these lactic acid bacteria, dead cells of these lactic acid bacteria, or a treatment product of these lactic acid bacteria, an infection preventative/therapeutic containing as an active ingredient a peptide glycan of these lactic acid bacteria, and a food/beverage containing these are disclosed.

Abstract: Provided are: a novel compound having a structure different from that of existing drugs; a novel microorganism capable of producing the novel compound; and further; a novel compound effective to a multiple-drug-resistant bacterium. To provide a novel compound having a high therapeutic effect which can be expected to have a low hurdle for practical realization by selecting an intended compound from many candidate compounds based not only on an antibacterial activity but also on evaluation including a therapeutic effect, a cyclic peptide compound shown by the following formula (1) or a pharmaceutically allowable salt thereof and a microorganism with Accession No. NITE BP-870 or a microorganism mutated naturally or artificially therefrom are provided. (In the formula (1), R1 represents an acyl group having 7, 8, or 9 carbon atoms and optionally containing a substituent group; R2 represents a methyl group or a hydrogen atom; and R3 represents an ethyl group or a methyl group.

Abstract: Provided are: a novel compound having a structure different from that of existing drugs; a novel microorganism capable of producing the novel compound; and further; a novel compound effective to a multiple-drug-resistant bacterium. To provide a novel compound having a high therapeutic effect which can be expected to have a low hurdle for practical realization by selecting an intended compound from many candidate compounds based not only on an antibacterial activity but also on evaluation including a therapeutic effect, a cyclic peptide compound shown by the following formula (1) or a pharmaceutically allowable salt thereof and a microorganism with Accession No. NITE BP-870 or a microorganism mutated naturally or artificially therefrom are provided. (In the formula (1), R1 represents an acyl group having 7, 8, or 9 carbon atoms and optionally containing a substituent group; R2 represents a methyl group or a hydrogen atom; and R3 represents an ethyl group or a methyl group.

Abstract: It is intended to provide an evaluation method and a screening method capable of eliminating a substance that disturbs in vivo kinetics in an individual and capable of simply and easily searching a substance having an action of activating/suppressing an innate immune mechanism without being affected by LPS derived from bacteria, which can be contaminated during the search, as well as a drug and a food for activating/suppressing the innate immune mechanism, and methods of producing the same. The present invention provides a method of evaluating or screening the substance having the action of activating/suppressing the innate immune mechanism using a muscular contraction of an organism having the innate immune mechanism as an indicator, and methods of producing the drug and the food for activating/suppressing the innate immune mechanism.

Abstract: It is intended to provide an evaluation method and a screening method capable of eliminating a substance that disturbs in vivo kinetics in an individual and capable of simply and easily searching a substance having an action of activating/suppressing an innate immune mechanism without being affected by LPS derived from bacteria, which can be contaminated during the search, as well as a drug and a food for activating/suppressing the innate immune mechanism, and methods of producing the same. The present invention provides a method of evaluating or screening the substance having the action of activating/suppressing the innate immune mechanism using a muscular contraction of an organism having the innate immune mechanism as an indicator, and methods of producing the drug and the food for activating/suppressing the innate immune mechanism.